Abstract
Tumor hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression are important factors influencing treatment response and selection in patients with metastatic breast cancer (mBC). Using the LifeLink Oncology Analyzer Database, we classified mBC patients by combined HR and HER2 status, and evaluated the use of pharmacological treatment modalities both overall and within these subtypes in Western Europe. The study population included 4670 women with mBC from five Western European countries (France, Germany, Italy, Spain, UK). The most recent treatment administered (use of chemotherapy, endocrine therapy, HER2-targeted therapy, or others) and tumor marker (HR and HER2) status were captured. The results were summarized descriptively by combined tumor receptor status, current therapy type at the time of the survey, and age. Combined tumor receptor status and the most recent treatment for mBC were known for 4070 and 4060 women, respectively. The proportion of patients with each subtype ranged from 12.6-53.5% of the overall population (HR-/HER2+ least common and HR+/HER2- most common). Overall, chemotherapy was the most frequently reported treatment used followed by endocrine therapy and HER2-targeted therap...Continue Reading
References
Jan 9, 1987·Science·D J SlamonW L McGuire
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F RévillionJ P Peyrat
Mar 14, 2000·Steroids·A M Brodie, V C Njar
Jul 8, 2003·The Journal of Pathology·Caroline J WittonJohn M S Bartlett
May 4, 2005·Breast Cancer Research and Treatment·Huei-Jean HuangIgnace Vergote
Jul 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BeslijaH Zwierzina
Feb 9, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J FerlayP Boyle
Mar 28, 2007·Cancer·Katrina R BauerVincent Caggiano
Nov 13, 2007·Advances in Experimental Medicine and Biology·Ana Maria Gonzalez-AnguloGabriel N Hortobagyi
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Mar 8, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C HéryP Autier
May 9, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V KatajaUNKNOWN ESMO Guidelines Working Group
Dec 23, 2008·Breast Cancer Research and Treatment·Joseph Gligorov, Jean-Pierre Lotz
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jul 4, 2009·Clinical Medicine & Research·Adedayo A OnitiloBickol N Mukesh
Jul 18, 2009·The Oncologist·Valentina Guarneri, PierFranco Conte
Mar 20, 2010·Current Pharmacogenomics and Personalized Medicine·R NahtaD L Rowe
Apr 12, 2011·Pathology Oncology Research : POR·Adele CaldarellaMarco Zappa
Feb 15, 2012·International Journal of Breast Cancer·P PronzatoM E Cazzaniga
Citations
Nov 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J A LobbezooV C G Tjan-Heijnen
Jun 17, 2015·International Journal of Breast Cancer·Nanxin LiEric Q Wu
Apr 20, 2014·Journal of breast cancer·Jie ChenXi Wu
Jun 2, 2020·The Oncologist·Liang JinQiang Liu
Jun 6, 2017·BMC Cancer·Giovanni ZanottiMonique Martin
Mar 2, 2021·Frontiers in Oncology·Yun WuBinghe Xu
Dec 5, 2017·Clinical Breast Cancer·Samantha K KuroskyJames A Kaye